Crispr Therapeutics announced that the FDA has approved Casgevy, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
- Crispr Therapeutics call volume above normal and directionally bullish
- Baird finds ‘incremental negative’ in Crispr’s 2024 outlook
- Crispr Therapeutics announces 2024 outlook
- Crispr Therapeutics put volume heavy and directionally bearish